SMAD2 and chronic myelogenous leukemia, BCR-ABL1 positive: Activin A via non-canonical SMAD2 signalling can also activate β-catenin leading to upregulation of the TCF/LEF transcriptional regulators38, a pathway well described in CML progression and TKI resistance40.